@article{1dd69978bd704b3faf1323ba728bcb04,
title = "Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach",
keywords = "immuno-PET, Zirconium-89, cetuximab, LAHNSCC, EGFR, GROWTH-FACTOR RECEPTOR, CELL LUNG-CANCER, EGFR EXPRESSION, MACH-NC, CHEMOTHERAPY, SURVIVAL, RADIOTHERAPY, ZR-89, IMMUNOHISTOCHEMISTRY, METAANALYSIS",
author = "Even, {Aniek J. G.} and Olga Hamming-Vrieze and {van Elmpt}, Wouter and Winnepenninckx, {Veronique J. L.} and Jolien Heukelom and Tesselaar, {Margot E. T.} and Vogel, {Wouter V.} and Ann Hoeben and Zegers, {Catharina M. L.} and Vugts, {Danielle J.} and {van Dongen}, {Guus A. M. S.} and Harry Bartelink and Mottaghy, {Felix M.} and Frank Hoebers and Philippe Lambin",
year = "2017",
month = jan,
day = "17",
doi = "10.18632/oncotarget.13910",
language = "English",
volume = "8",
pages = "3870--3880",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "3",
}